Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations".”
UnverifiableConfidence: LOW

Reasoning

The claim states that the FDA is building on a specific guidance document titled "Psychedelic Drugs: Considerations for Clinical Investigations." Without any provided documents, statements, or references, there is no basis to verify whether such an action is occurring or has been announced.

On confidence: No supplied evidence was provided to confirm or refute the claim.

Important context

The claim pertains to FDA policy development regarding psychedelic drug research, which would typically be documented in FDA guidance releases or public statements.

Evidence

No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.

Limitations

The assessment is limited to the absence of supplied evidence; external sources were not consulted, and no inference can be made about the claim's truthfulness.

Last verified:
Oct 6, 2026, 4:16 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information

Federal Register · Drug Administration, Human Services Department, Food, Health